Wockhardt Limited (WOCKPHARMA) Fair Value & Analysis
Healthcare · IN · Market cap ₹317B
Fair value as of: Jul 3, 2026
From 24 valuation models · updated today
Share price −6.5% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹1,100 – ₹2,153 · fair‑value band ₹152.47 – ₹244.04 · the ₹1,939 price screens above the ₹217.81 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Wockhardt Limited (WOCKPHARMA) currently trades at ₹1,939, while our model-based Fair Value estimate is ₹217.81 — implying the stock looks roughly 88.8% overvalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Wockhardt Limited generated revenue of ₹33.7B at a net margin of 6.3%. Revenue grew 26.0% year over year. It earns a return on equity of 4.0%. Net debt stands at ₹19.8B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Wockhardt Limited reported revenue of ₹33.7B in FY2026 versus ₹32.3B in FY2022, a compound +1.1%/yr. Reported net income was ₹2.1B in FY2026.
Is WOCKPHARMA fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Wockhardt Limited (WOCKPHARMA) undervalued?
What is the fair value of WOCKPHARMA?
What is the quality score of WOCKPHARMA?
What is the revenue of Wockhardt Limited (WOCKPHARMA)?
What is the net profit margin of WOCKPHARMA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.